Evotec stock trades at EUR 3.14, down 0.63% pre-market
Published on 11/09/2026 at 07:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEvotec enters Monday with guidance intact
- Third-quarter adjusted EBITDA loss narrowed sharply from the prior-year period.
- Management maintained its full-year 2026 revenue and adjusted EBITDA outlook.
- The company is pursuing longer-term growth and profitability targets through its Horizon transformation.
Evotec stock traded at 3.14 euros on Lang & Schwarz at 07:54 CET on Monday, November 9, 2026, 0.63 percent below the Xetra close of Friday, November 6, at 3.16 euros.
Profitability improves in third quarter
In its November 5 release, Evotec said third-quarter revenue reached EUR 164.9 million, compared with EUR 163.9 million a year earlier. Adjusted Group EBITDA improved to a loss of EUR 1.6 million from a loss of EUR 15.0 million.
For the full year, management retained its reported revenue outlook of EUR 570 million to EUR 610 million and its adjusted EBITDA forecast of a loss of EUR 105 million to EUR 70 million. The company also outlined a longer-term ambition of approximately EUR 1 billion in annual group revenue by 2030.
Evotec combines drug discovery, development and manufacturing services. The unchanged outlook leaves execution of the Horizon transformation and the recovery in revenue as key issues for investors after the weaker nine-month sales trend.
Investors can follow the real-time quote of Evotec stock for further trading updates.
The DAX provides the relevant German equity-market backdrop for Evotec stock: current DAX market coverage.
More news and analyses on Evotec stock cover the company's earnings, outlook and market developments.
